Back

What are the unmet medical needs in secondary cardiovascular disease prevention?

28 August 2017 (12:55 - 13:07)
Organised by:
Congress Presentation Part of: Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol Atherosclerosis Open Access ESC Congress 2017

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

6 More presentations in this session

Presentation thumbnail
Welcome - Atherosclerosis and secondary cardiovascular disease prevention: inflammation and LDL-cholesterol.
Professor T. Luescher (London, GB)
Slides Video
Presentation thumbnail
Atherosclerosis and the cardiovascular continuum.
Professor P. Libby (Boston, US)
Slides Video
Presentation thumbnail
Cardiovascular residual risk: what are the markers?
Professor W. Koenig (Munich, DE)
Slides Video
Presentation thumbnail
Secondary cardiovascular disease prevention: what have we learnt from recent clinical trials?
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Audience Q&A and panel discussion - Atherosclerosis and secondary cardiovascular disease prevention: inflammation and LDL-cholesterol.
Professor P. Libby (Boston, US)
Slides Video

Access the full session

Session thumbnail
Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol

The Event

Event poster

ESC Congress 2017

28 August 2017 12:55 CET
You may be interested in
thumbnail
Webinar
How to Improve Implementation of Prevention Guidelines: Barriers, Tips and Tricks
9 December 2019
thumbnail
Congress Presentation
Exploring the unmet needs of cardiometabolic risk factors and medicines optimisation among post-myocardial infarction patients with diabetes
4 April 2025
thumbnail
Congress Presentation
Prognostic impact of secondary prevention medical therapy in patients with Takotsubo cardiomyopathy: a Bayesian network meta-analysis
2 September 2024
thumbnail
Webinar
Unmet needs in HF: patients with LVEF equal or above 40%
12 December 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources